← All indications
Bile Duct Neoplasms
Tumors or cancer of the BILE DUCTS.
Subtype terms (1)
More specific conditions that are subtypes of Bile Duct Neoplasms in the MeSH hierarchy.
- Common Bile Duct Neoplasms
2 drugs approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (17)
Phase 2 trials (99)
- azacitidine
- heparin
- afatinib
- anlotinib
- atezolizumab
- mk-1775
- olaparib
- azd-4547
- azd6738
- sorafenib
- becatecarin
- binimetinib
- cobimetinib
- devimistat
- dabrafenib
- dolastatin
- doxorubicin
- durvalumab
- olutasidenib
- vismodegib
- imatinib
- gm-ct-01
- trametinib
- gsk-2636771
- lapatinib
- hydroxychloroquine
- hydroxyurea
- palonosetron
- incomplete freund's adjuvant
- ramucirumab
- +69 more
Phase 1 trials (20)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (16)
- Eli Lilly
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Cancer Research Campaign
- Center Eugene Marquis
- Centre Georges Francois Leclerc
- University of London
- Harvard University
- Federation Francophone de Cancerologie Digestive
- Southwest Oncology Group
- UNICANCER
- University of Toronto
- University of California, Los Angeles
- Delcath Systems
- University of Lyon
- Moorgreen Hospital, Southampton
Organization Involved with Phase 2 Indications (54)
- Daiichi Sankyo
- Shire
- Merck
- Exelixis
- Sanofi
- AIO-Studien-gGmbH
- Baxalta
- Bayer
- Galectin Therapeutics Inc.
- Simcere Pharmaceutical Co., Ltd
- National Institutes of Health (NIH)
- Brown University
- Case Western Reserve University
- Cornell University
- Eastern Hepatobiliary Surgery Hospital
- Temple University
- Hacettepe University
- New Mexico Cancer Care Alliance
- NHS Lothian
- Northwestern University
- Ohio State University
- Paracelsus Medical University
- Stanford University
- Swiss Group for Clinical Cancer Research
- University of Edinburgh
- University of Hamburg
- University of New Mexico
- University of Salzburg
- University of South Florida
- University of Southern California
- +24 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (4)